SpecificationsOrganism/cell line/tissue*Homo sapiens*/pancreatic ductal adenocarcinoma and adjacent normal tissuesSexMale and femaleSequencer or array typeArraystar Human CircRNA Array (8 × 15K, Arraystar)Data formatRaw and analyzedExperimental factorsTumor vs. corresponding normal tissues from 4 pancreatic ductal adenocarcinoma patientsExperimental featuresMicroarray expression profile analysis of circular RNAs in human pancreatic ductal adenocarcinomaConsentAll patients provided written informed consentSample source locationXi\'an, China

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69362>

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Tissue samples {#s0015}
-------------------

The Ethics Review Board of Xijing Hospital (No: XJYYLL-2015075) approved the study. Tissue samples were prospectively collected from patients undergoing operation at the Department of Hepatobiliary Surgery at the Xijing Hospital. Tumor and adjacent normal pancreatic tissue samples were snap-frozen in liquid nitrogen immediately after resection and stored at − 130 °C until use. Histology of the tissue specimen was confirmed by two uropathologists.

2.2. RNA preparation {#s0020}
--------------------

Total RNA was isolated from 4 PDAC samples and paired adjacent normal tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer\'s protocol. Total RNA from each specimen was quantified and quality was verified using NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA). Additionally, RNA integrity was assessed by electrophoresis on a denaturing agarose gel.

2.3. Labeling and hybridization {#s0025}
-------------------------------

Sample labeling and array hybridization were performed according to the manufacturer\'s protocol (Arraystar, Rockville, Maryland, USA). In short, circRNAs were treated with Ribonuclease R (RNase R) to remove linear RNAs according to the manufacturer\'s protocol (Epicenter, Madison, WI, USA). Then, each sample was amplified and transcribed into fluorescent cRNA utilizing a random priming method with a Super RNA Labeling Kit (Arraystar). The labeled cRNAs were purified using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg cRNA) were measured using NanoDrop ND-1000. Then, 1 μg of each labeled cRNA was fragmented by adding 5 μl 10 × Blocking Agent and 1 μl of 25 × Fragmentation Buffer. The mixture was heated at 60 °C for 30 min, and 25 μl 2 × Hybridization buffer was added to dilute the labeled cRNA. Then, 50 μl of the hybridization solution was dispensed into the gasket slide, which was assembled with Human Circular RNA Array slides. The slides were incubated for 17 h at 65 °C in an Agilent Hybridization Oven. The hybridized arrays were washed, fixed and scanned using an Agilent G2505C Scanner.

2.4. Microarray and quality control {#s0030}
-----------------------------------

Scanned images were imported into Agilent Feature Extraction software (version 11.0.1.1) for raw data extraction. Quantile normalization of raw data and subsequent data processing were performed using the R software package (R version 3.1.2). After quantile normalization of the raw data, low intensity filtering was performed, and circRNAs with at least 2 out of 8 samples that had flags in "P" or "M" ("All Targets Value") were retained for further analyses. The log2-ratio was used for quantile normalization. CircRNAs differentially expressed between the two groups were conveniently estimated by fold-change filtering and Student\'s t-test. CircRNAs exhibiting fold changes ≥ 2.0 and p-values ≤ 0.05 were selected as significantly differentially expressed circRNAs.

The experiment workflow is listed in [Fig. 1](#f0005){ref-type="fig"}.

3. Discussion {#s0035}
=============

Large amounts of circRNAs are recently discovered and represent a new special class of endogenous noncoding RNA. Recent researches have revealed that circRNAs are an abundant, stable, diverse and conserved class of RNA molecules [@bb0005], [@bb0010], [@bb0015]. Moreover, circRNAs can function as miRNA sponges or regulate parent gene expression to affect disease initiation and progression [@bb0020], [@bb0025], [@bb0030], [@bb0035]. These studies indicate that circRNAs have great potential to become diagnostic or predictive biomarkers of disease and provide new insights into the treatment of diseases. In this study, we have explored the expression profile of circRNAs in 4 PDAC samples and paired adjacent normal tissues. We have also revealed that the circRNA expression signatures of PDAC are dysregulated. The identification of novel differentially expressed circRNAs is a crucial step towards better understanding of PDAC. These findings indicate that circRNAs can be involved in the initiation and progression of PDAC.
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